Investing.com – Biomarin Pharma (NASDAQ:) reported on Wednesday third quarter that beat analysts’ forecasts and revenue that fell short of expectations.
Biomarin Pharma announced earnings per share of $-0.2 on revenue of $408.7M. Analysts polled by Investing.com anticipated EPS of $-0.2427 on revenue of $435.89M.
Biomarin Pharma shares are down 18.21% from the beginning of the year and are trading at $71.50 , down-from-52-week-high.They are under-performing the Nasdaq which is up 18.21% from the start of the year.
Biomarin Pharma shares lost 0.31% in after-hours trade the report.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma’s report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.
Thermo Fisher Scientific had beat expectations on Wednesday with third quarter EPS of $5.76 on revenue of $9.33B, compared to forecast for EPS of $4.68 on revenue of $8.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.